Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer

Next Previous
Trial Profile

A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms KeyLargo

    • Most Recent Events

    • 06 Jun 2023 Results of a retrospective analysis (n=36) using plasma samples from this trial focusing on tumor-informed ctDNA approach as a tool for longitudinal disease monitoring and dynamic tumor evolution presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 30 May 2023 According to a Personalis media release, results assessing the ctDNA levels and their utility for longitudinal disease monitoring and surveillance of dynamic tumor evolution using patient samples from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.
    • 30 May 2023 Results assessing the ctDNA levels and their utility for longitudinal disease monitoring and surveillance of dynamic tumor evolution using Personalis' NeXT Personal platform using patients samples from this trial presented in the Personalis Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top